Mike Kratky
Stock Analyst at Leerink Partners
(3.43)
# 827
Out of 4,827 analysts
27
Total ratings
47.37%
Success rate
32.92%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBNX Beta Bionics | Initiates: Outperform | $28 | $14.37 | +94.85% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $8.35 | +43.80% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $83.35 | +4.38% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $157.14 | +25.37% | 2 | Sep 10, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $289.00 | -9.00% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $22.26 | +102.16% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $12.08 | +82.12% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $262.12 | -29.80% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $40.51 | +3.68% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $536.15 | -36.21% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $74.98 | +0.03% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $52.98 | -30.16% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $16.35 | -44.94% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $2.75 | +1,718.18% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.42 | +3,069.01% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $298.58 | +5.50% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $29.07 | +6.64% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $13.88 | +0.86% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $12.27 | +226.00% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $0.82 | +5,754.37% | 1 | Aug 11, 2022 |
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $14.37
Upside: +94.85%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $8.35
Upside: +43.80%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $83.35
Upside: +4.38%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $157.14
Upside: +25.37%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $289.00
Upside: -9.00%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $22.26
Upside: +102.16%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $12.08
Upside: +82.12%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $262.12
Upside: -29.80%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $40.51
Upside: +3.68%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $536.15
Upside: -36.21%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $74.98
Upside: +0.03%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $52.98
Upside: -30.16%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $16.35
Upside: -44.94%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $2.75
Upside: +1,718.18%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.42
Upside: +3,069.01%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $298.58
Upside: +5.50%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $29.07
Upside: +6.64%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $13.88
Upside: +0.86%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $12.27
Upside: +226.00%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $0.82
Upside: +5,754.37%